The research for development of polyvalent lived vaccine based on current varicella vaccine

Abstract

Varicella-zoster virus (VZV) infection is a causative agent of varicella and zoster. Varicella vaccine has been developed to reduce the morbidity of varicella. The Oka vaccine is the only attenuated live varicella vaccine permitted for use by WHO.
Recently we have generated a recombinant virus expressing mumps virus (MuV) HN protein based on the varicella vaccine. The recombinant virus could induce neutralizing antibodies against both VZV and MuV in guinea pig, thus indicating that the virus may be a candidate for polyvalent live vaccine against MuV and VZV infection.
Here we have summarized about the Oka vaccine, the recombinant virus and the application for a polyvalent live vaccine of the recombinant virus.